AMG 151 (ARRY-403), a Novel Glucokinase Activator, Decreases Fasting and Postprandial Glycemia in Patients With Type 2 Diabetes.

AMG 151 (ARRY-403), a Novel Glucokinase Activator, Decreases Fasting and Postprandial Glycemia in Patients With Type 2 Diabetes.
Diabetes Obes Metab. 2015 Oct 5;
Authors: Katz L, Manamley N, Snyder W, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, Kewalramani R, Pellacani A
Abstract
Phase 1 studies have demonstrated that AMG 151 activates glucokinase, a key enzyme in glucose homeostasis. This randomized, placebo-controlled phase 2a study evaluated the dose-effect relationship of the glucokinase activator AMG 151 relative to placebo on fasting plasma glucose (FPG) in 236 patients (n=33-35/arm) with type 2 diabetes treated with metformin. Patients received oral AMG 151 at 50, 100, or 200 mg twice daily (BID); AMG 151 at 100, 200, or 400 mg once daily (QD); or matching placebo for 28 days. A significant linear dose-effect trend was observed with the BID regimen (p = 0.004) for change in FPG to day 28; no trend was observed with the QD regimen. A higher incidence of hypoglycemia and hypertriglyceridemia was observed with AMG 151 administration. AMG 151 significantly reduced FPG when administered BID but not when administered QD in patients with type 2 diabetes treated with metformin.
PMID: 26434934 [PubMed - as supplied by publisher]

Source: Diabetes Metab - October 5, 2015 Category: Endocrinology Authors: Katz L, Manamley N, Snyder W, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, Kewalramani R, Pellacani A Tags: Diabetes Obes Metab Source Type: research